Tags

Type your tag names separated by a space and hit enter

Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
J Clin Oncol. 2009 Jul 10; 27(20):3303-11.JC

Abstract

PURPOSE

Circulating tumor cells (CTCs) and [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) are two new promising tools for therapeutic monitoring. In this study, we compared the prognostic value of CTC and FDG-PET/CT monitoring during systemic therapy for metastatic breast cancer (MBC).

PATIENTS AND METHODS

A retrospective analyses of 115 MBC patients who started a new line of therapy and who had CTC counts and FDG-PET/CT scans performed at baseline and at 9 to 12 weeks during therapy (midtherapy) was performed. Patients were categorized according to midtherapy CTC counts as favorable (ie, < five CTCs/7.5 mL blood) or unfavorable (> or = five CTCs/7.5 mL blood) outcomes. CTC counts and FDG-PET/CT response at midtherapy were compared, and univariate and multivariate analyses were performed to identify factors associated with survival.

RESULTS

In 102 evaluable patients, the median overall survival time was 14 months (range, 1 to > 41 months). Midtherapy CTC levels correlated with FDG-PET/CT response in 68 (67%) of 102 evaluable patients. In univariate analysis, midtherapy CTC counts and FDG-PET/CT response predicted overall survival (P < .001 and P = .001, respectively). FDG-PET/CT predicted overall survival (P = .0086) in 31 (91%) of 34 discordant patients who had fewer than five CTCs at midtherapy. Only midtherapy CTC levels remained significant in a multivariate analysis (P = .004).

CONCLUSION

Detection of five or more CTCs during therapeutic monitoring can accurately predict prognosis in MBC beyond metabolic response. FDG-PET/CT deserves a role in patients who have fewer than five CTCs at midtherapy. Prospective trials should evaluate the most sensitive and cost-effective modality for therapeutic monitoring in MBC.

Authors+Show Affiliations

The University of Texas M. D. Anderson Cancer Center, Houston, 77030, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19451443

Citation

De Giorgi, Ugo, et al. "Circulating Tumor Cells and [18F]fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Outcome Prediction in Metastatic Breast Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 27, no. 20, 2009, pp. 3303-11.
De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27(20):3303-11.
De Giorgi, U., Valero, V., Rohren, E., Dawood, S., Ueno, N. T., Miller, M. C., Doyle, G. V., Jackson, S., Andreopoulou, E., Handy, B. C., Reuben, J. M., Fritsche, H. A., Macapinlac, H. A., Hortobagyi, G. N., & Cristofanilli, M. (2009). Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 27(20), 3303-11. https://doi.org/10.1200/JCO.2008.19.4423
De Giorgi U, et al. Circulating Tumor Cells and [18F]fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Outcome Prediction in Metastatic Breast Cancer. J Clin Oncol. 2009 Jul 10;27(20):3303-11. PubMed PMID: 19451443.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. AU - De Giorgi,Ugo, AU - Valero,Vicente, AU - Rohren,Eric, AU - Dawood,Shaheenah, AU - Ueno,Naoto T, AU - Miller,M Craig, AU - Doyle,Gerald V, AU - Jackson,Summer, AU - Andreopoulou,Eleni, AU - Handy,Beverly C, AU - Reuben,James M, AU - Fritsche,Herbert A, AU - Macapinlac,Homer A, AU - Hortobagyi,Gabriel N, AU - Cristofanilli,Massimo, Y1 - 2009/05/18/ PY - 2009/5/20/entrez PY - 2009/5/20/pubmed PY - 2009/9/17/medline SP - 3303 EP - 11 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 27 IS - 20 N2 - PURPOSE: Circulating tumor cells (CTCs) and [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) are two new promising tools for therapeutic monitoring. In this study, we compared the prognostic value of CTC and FDG-PET/CT monitoring during systemic therapy for metastatic breast cancer (MBC). PATIENTS AND METHODS: A retrospective analyses of 115 MBC patients who started a new line of therapy and who had CTC counts and FDG-PET/CT scans performed at baseline and at 9 to 12 weeks during therapy (midtherapy) was performed. Patients were categorized according to midtherapy CTC counts as favorable (ie, < five CTCs/7.5 mL blood) or unfavorable (> or = five CTCs/7.5 mL blood) outcomes. CTC counts and FDG-PET/CT response at midtherapy were compared, and univariate and multivariate analyses were performed to identify factors associated with survival. RESULTS: In 102 evaluable patients, the median overall survival time was 14 months (range, 1 to > 41 months). Midtherapy CTC levels correlated with FDG-PET/CT response in 68 (67%) of 102 evaluable patients. In univariate analysis, midtherapy CTC counts and FDG-PET/CT response predicted overall survival (P < .001 and P = .001, respectively). FDG-PET/CT predicted overall survival (P = .0086) in 31 (91%) of 34 discordant patients who had fewer than five CTCs at midtherapy. Only midtherapy CTC levels remained significant in a multivariate analysis (P = .004). CONCLUSION: Detection of five or more CTCs during therapeutic monitoring can accurately predict prognosis in MBC beyond metabolic response. FDG-PET/CT deserves a role in patients who have fewer than five CTCs at midtherapy. Prospective trials should evaluate the most sensitive and cost-effective modality for therapeutic monitoring in MBC. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/19451443/Circulating_tumor_cells_and_[18F]fluorodeoxyglucose_positron_emission_tomography/computed_tomography_for_outcome_prediction_in_metastatic_breast_cancer_ L2 - https://ascopubs.org/doi/10.1200/JCO.2008.19.4423?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -